Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients

NCT07015242 is registered in ClinicalTrials.gov with Juno Therapeutics, Inc., a Bristol-Myers Squibb Company as lead sponsor.

NCT NCT07015242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07015242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The CAROLYN Trial: Lisocabtagene Maraleucel as First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase
Phase 2
Overall status
Recruiting
Start date
November 6, 2025
Completion date
December 10, 2028
Enrollment
65 (estimated)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma